Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.43 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13110932 | 0.89 | HDAC1 (0.49) | HDAC1HDAC2HDAC3NCOR2HDAC4 | |
| SCHEMBL13110941 | 0.84 | HDAC1 (0.48) | HDAC1HDAC2HDAC3NCOR2HDAC4 | |
| SCHEMBL13110973 | 0.79 | HDAC1 (0.56) | HDAC1HDAC2HDAC3NCOR2NCOR1 | |
| SCHEMBL13110895 | 0.78 | HDAC1 (0.50) | HDAC1HDAC2HDAC3NCOR2HDAC4 | |
| SCHEMBL13111100 | 0.78 | PTGS1 (0.48) | HDAC1HDAC2HDAC3NCOR2HDAC8 | |
| SCHEMBL13110903 | 0.76 | HDAC1 (0.46) | HDAC1HDAC2HDAC3NCOR2NCOR1 | |
| SCHEMBL13110913 | 0.75 | HDAC1 (0.45) | HDAC1HDAC2HDAC3NCOR2HDAC4 | |
| SCHEMBL13110939 | 0.73 | HDAC1 (0.59) | HDAC1HDAC2HDAC3NCOR2HDAC4 | |
| SCHEMBL10373334 | 0.72 | HDAC1 (0.71) | HDAC1HDAC2HDAC3NCOR2HDAC4 | |
| SCHEMBL13111107 | 0.72 | HDAC1 (0.44) | HDAC1HDAC2HDAC3NCOR2NCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267779-A1 | Novel Compounds and Methods of Using Them | SYNDAX PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267779-A1 | Novel Compounds and Methods of Using Them | SYNDAX PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2009015237-A1 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267779-A1 | Novel Compounds and Methods of Using Them | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC2 6/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.